Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enhanta
- Development stage
- Preclinical
- Lead developer
- Arstat Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Enhanta** is an investigational, proprietary, fixed-dose oral non-hormonal combination being developed by Arstat Pharmaceuticals for painful and heavy menstrual periods. It combines an unspecified nonsteroidal anti-inflammatory drug with low-dose tranexamic acid, aiming to relieve dysmenorrhea while reducing excessive menstrual blood loss in menorrhagia. Arstat describes prescription and over-the-counter formulations and characterizes the program as Phase IIb-ready, with a potential Phase III pathway subject to FDA confirmation. ([arstatinfo.com](https://www.arstatinfo.com/enhanta))
- Other names
- Enhanta
02
Targets
COX
Beyond the preview
Go deeper on Enhanta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enhanta.